Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

HAB Nicolai Johannsen

Fast Optical Sectioning of Developing Organisms and Tissue Microstructures

ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.

ZEISS Insights: Measurement of bone plates and screws

Get free access to technical paper.

He takes over the chairmanship of Karolinska Development

Ben Toogood is appointed as the new chairman of Karolinska Developments.

GSK pays 2.2 billion dollars to settle Zantac lawsuits

British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against t...

The US is leaving the WHO

The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

How to transport hydrogen - the BionicHydrogenBattery

Have you ever wondered how hydrogen should be transported and stored safely. Well, here is a solution for all who is interested in making a true infrastructure work.

“Life science is important on a personal level”

From the High Coast to the Government Offices. Jeanette Edblad is a native of Ångermanland, and since September last year, she has been Head and Coordinator of ...

Learn from Speakers from Leading MedTech Companies

Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Samuel Lagercrantz: We are currently seeing medical breakthroughs in these areas

Samuel Lagercrantz, Editor in Chief of Life Science Sweden, lists three medical fields in which we are currently seeing major breakthroughs and two fields in wh...

How to optimise your liquid handling results

In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...

Orbán's extended arm becomes health commissioner in the EU

Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hung...

The new Swedish life science strategy – “It will consolidate Sweden as a leader”

Clinical trials and precision health are emphasised as key areas in the new national life science strategy.

AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.

Topp 20-listor: Sveriges främsta forskare inom molekylär- och mikrobiologi

Mathias Uhlén, Staffan Normark, Joakim Dillner och Carl-Henrik Heldin är namnen som återfinns högst på listorna över Sveriges mest citerade forskare inom mikrob...

Quretech granted a European patent for a new type of antibiotic

The European patent provides protection until 2041. Previously, the patent was granted in China, and the application is currently under review in the USA, India, and Japan.

Topp 20-listor: Här är främsta forskarna inom immunologi och genetik

Lars Klareskog och Tomas Olsson vid Karolinska institutet rankas som Sveriges främsta forskare inom immunologi. Juha Kere, också Karolinska, är etta på listan ö...

ZEISS Metrology Expert Tips

New video series provides valuable expert knowledge.

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.